Compare Corning Incorporated (GLW) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Moderna, Inc. — how do they compare? Corning Incorporated trades at $156.14 (market cap $131.65B), while Moderna, Inc. trades at $208.24 (market cap $78.65B). The key difference: Corning Incorporated is the larger of the two by market cap, and Corning Incorporated pays a 0.73% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 35 Days and Moderna, Inc. for 59 Days on average.
| GLW | MRNA | |
|---|---|---|
Market Cap | $131.65B | $78.65B |
Volume | 8,992,522 | 37,373,437 |
Sector | Technology | Health |
52-Week High | $255.79 | $203.46 |
52-Week Low | $78.03 | $22.36 |
Typical Hold Time | 35 Days | 59 Days |
Enterprise Value | $138.52B | $74.80B |
Dividend Yield | 0.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLW trades at $163.21, down 3.41% today, with a bullish technical signal and strong analyst support (56.75% buy ratings). Recent fundamentals show robust revenue growth to $15.63B in 2025 and net income of $1.60B, though valuation ratios like P/E of 70.43 appear elevated. The company secured a significant $3B+ fiber supply deal with AT&T, driving positive sentiment amid AI infrastructure demand.
Outlook is positive with earnings beats and a consensus price target of $171.25 offering ~5% upside. Key risks include high debt levels, patent litigation, and sensitivity to tech spending cycles. Institutional confidence remains high given operational cash flow strength and strategic positioning in fiber optics.
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
